JP2021515599A5 - - Google Patents

Info

Publication number
JP2021515599A5
JP2021515599A5 JP2020571344A JP2020571344A JP2021515599A5 JP 2021515599 A5 JP2021515599 A5 JP 2021515599A5 JP 2020571344 A JP2020571344 A JP 2020571344A JP 2020571344 A JP2020571344 A JP 2020571344A JP 2021515599 A5 JP2021515599 A5 JP 2021515599A5
Authority
JP
Japan
Prior art keywords
seq
cytokine
prodrug according
polypeptide
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020571344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021515599A (ja
JP7515412B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/021654 external-priority patent/WO2019173832A2/en
Publication of JP2021515599A publication Critical patent/JP2021515599A/ja
Publication of JP2021515599A5 publication Critical patent/JP2021515599A5/ja
Priority to JP2024106766A priority Critical patent/JP7820448B2/ja
Application granted granted Critical
Publication of JP7515412B2 publication Critical patent/JP7515412B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020571344A 2018-03-09 2019-03-11 新規のサイトカインプロドラッグ Active JP7515412B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024106766A JP7820448B2 (ja) 2018-03-09 2024-07-02 新規のサイトカインプロドラッグ

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201862640969P 2018-03-09 2018-03-09
US62/640,969 2018-03-09
US201862643104P 2018-03-14 2018-03-14
US62/643,104 2018-03-14
US201862644384P 2018-03-17 2018-03-17
US62/644,384 2018-03-17
US201862644577P 2018-03-18 2018-03-18
US62/644,577 2018-03-18
US201862680707P 2018-06-05 2018-06-05
US62/680,707 2018-06-05
US201962801649P 2019-02-06 2019-02-06
US62/801,649 2019-02-06
PCT/US2019/021654 WO2019173832A2 (en) 2018-03-09 2019-03-11 Novel cytokine prodrugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024106766A Division JP7820448B2 (ja) 2018-03-09 2024-07-02 新規のサイトカインプロドラッグ

Publications (3)

Publication Number Publication Date
JP2021515599A JP2021515599A (ja) 2021-06-24
JP2021515599A5 true JP2021515599A5 (enExample) 2022-03-23
JP7515412B2 JP7515412B2 (ja) 2024-07-12

Family

ID=66175477

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020571344A Active JP7515412B2 (ja) 2018-03-09 2019-03-11 新規のサイトカインプロドラッグ
JP2024106766A Active JP7820448B2 (ja) 2018-03-09 2024-07-02 新規のサイトカインプロドラッグ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024106766A Active JP7820448B2 (ja) 2018-03-09 2024-07-02 新規のサイトカインプロドラッグ

Country Status (6)

Country Link
US (2) US20210260163A1 (enExample)
EP (1) EP3762406A2 (enExample)
JP (2) JP7515412B2 (enExample)
CN (1) CN113166220A (enExample)
CA (1) CA3115461A1 (enExample)
WO (1) WO2019173832A2 (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019005756A (es) 2016-11-28 2019-08-14 Chugai Pharmaceutical Co Ltd Dominio de union al antigeno y polipeptido que incluye seccion de transporte.
TW202235438A (zh) 2016-11-28 2022-09-16 日商中外製藥股份有限公司 能夠調節配體結合活性的配體結合分子
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
TWI901940B (zh) 2017-08-03 2025-10-21 美商安進公司 介白素-21突變蛋白及治療方法
KR20250145137A (ko) 2017-08-03 2025-10-13 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
TWI880235B (zh) 2017-11-28 2025-04-11 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
EP3719035A4 (en) 2017-11-28 2021-09-01 Chugai Seiyaku Kabushiki Kaisha POLYPEPTIDE WITH ANTIGEN-BINDING AREA AND CARRYING SECTION
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
JP2019122373A (ja) 2018-01-12 2019-07-25 アムジエン・インコーポレーテツド 抗ｐｄ−１抗体及び治療方法
WO2019222294A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
US20210130430A1 (en) 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
CN113840832A (zh) 2018-05-14 2021-12-24 狼人治疗公司 可活化白介素-2多肽及其使用方法
EP3824096A4 (en) * 2018-07-18 2022-04-20 AskGene Pharma Inc. NOVEL ANTIBODIES AND METHODS FOR THE PRODUCTION AND USE THEREOF
CN112534052B (zh) 2018-07-25 2024-09-20 奥美药业有限公司 全新il-21前药及使用方法
US12269855B2 (en) 2018-09-21 2025-04-08 Innovent Biologics (Suzhou) Co., Ltd. Interleukin-2 and use thereof
EP3854805A4 (en) * 2018-09-21 2022-08-24 Innovent Biologics (Suzhou) Co., Ltd. NOVEL INTERLEUKIN 2 AND ITS USE
MX2021003543A (es) 2018-09-27 2021-06-23 Xilio Dev Inc Polipeptidos de citocinas enmascaradas.
US20200246467A1 (en) 2019-02-06 2020-08-06 Synthorx, Inc. Il-2 conjugates and methods of use thereof
CN121971599A (zh) 2019-02-25 2026-05-05 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
JP2022533254A (ja) * 2019-05-24 2022-07-21 プロヴィヴァ セラピューティクス （ホン コン） リミテッド Ｉｌ－２組成物およびその使用方法
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
EP4004026A4 (en) * 2019-07-25 2023-11-15 Trutino Biosciences Inc. IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER
WO2021024020A1 (en) * 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
AU2020329216A1 (en) * 2019-08-12 2022-02-24 AskGene Pharma, Inc. IL-2 fusion proteins that preferentially bind ILl-2ralpha
MX2022002740A (es) 2019-09-10 2022-03-25 Synthorx Inc Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
AU2020353235A1 (en) * 2019-09-28 2022-03-31 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
CN115151279B (zh) * 2019-12-13 2026-05-05 科优基因公司 基于细胞因子的可生物活化药物及其使用方法
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
JP7579344B2 (ja) 2019-12-23 2024-11-07 シンソークス， インコーポレイテッド Ｎ６－（（２－アジドエトキシ）カルボニル）リシンを製造する方法
JP2023514010A (ja) 2020-01-10 2023-04-05 ブライト ピーク セラピューティクス エージー 修飾ｉｌ－２ポリペプチドおよびその使用
JP7767290B2 (ja) * 2020-01-11 2025-11-11 アスクジーン・ファーマ・インコーポレイテッド 新規なマスクされたサイトカインおよびその使用方法
KR20220128413A (ko) * 2020-01-15 2022-09-20 트루티노 바이오사이언시스 인코포레이티드 절단성 링커를 포함하는 사이토카인 il-2 프로드러그
WO2021149697A1 (en) * 2020-01-20 2021-07-29 Chugai Seiyaku Kabushiki Kaisha Ligand-binding fusion proteins
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
MX2022011676A (es) * 2020-03-23 2023-03-08 Zymeworks Bc Inc Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
PH12022552630A1 (en) * 2020-04-01 2023-01-04 Xilio Dev Inc Masked il-15 cytokines and their cleavage products
IL296915A (en) * 2020-04-01 2022-12-01 Xilio Dev Inc Masked il-2 cytokines and their cleavage products
CN115734806A (zh) * 2020-04-01 2023-03-03 西里欧发展公司 掩蔽的il-12细胞因子和其切割产物
JP2023520922A (ja) 2020-04-10 2023-05-22 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能サイトカイン構築物および関連組成物ならびに方法
WO2021222762A2 (en) * 2020-04-30 2021-11-04 Aetio Biotherapy, Inc. Activatable il2 composition and methods of use
JP2023526282A (ja) 2020-05-13 2023-06-21 ボナム セラピューティクス，インク． タンパク質複合体の組成物及びその使用方法
US20220033784A1 (en) * 2020-07-14 2022-02-03 Pfizer Inc. Recombinant vaccinia virus
CN116323653A (zh) 2020-09-04 2023-06-23 山东先声生物制药有限公司 Il-2突变体及其应用
JP2023540629A (ja) * 2020-09-16 2023-09-25 ベイジーン リミテッド インターロイキン１５構築物及び使用方法
CN117500518A (zh) * 2020-09-18 2024-02-02 地方独立行政法人 宫城县立医院机构 Il-2突变蛋白及包含其的药物
TW202406932A (zh) * 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
JP2023553323A (ja) 2020-11-25 2023-12-21 エクシリオ デベロップメント， インコーポレイテッド 腫瘍特異的に切断可能なリンカー
US20240076331A1 (en) * 2021-02-01 2024-03-07 AskGene Pharma, Inc. Chimeric Molecules Comprising an IL-10 or TGF-Beta Agonist Polypeptide
CN112553256B (zh) * 2021-02-20 2021-06-22 北京百普赛斯生物科技股份有限公司 Il-2受体复合物及其制备方法与应用
CA3211924A1 (en) 2021-03-16 2022-09-22 Sayantan Mitra Masked activatable cytokine constructs and related compositions and methods
JP7642857B2 (ja) * 2021-04-22 2025-03-10 広東菲鵬制▲薬▼股▲ふん▼有限公司 二重特異性多機能性融合ポリペプチド
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
AU2022292592A1 (en) * 2021-06-17 2024-01-25 Fuse Biosciences (Hong Kong) Limited Immunoconjugate molecules and related methods and compositions thereof
WO2023281485A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
WO2023281482A1 (en) * 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Cd20-targeted il-2 and its uses
CN117615792A (zh) * 2021-07-09 2024-02-27 明峰治疗股份公司 检查点抑制剂与il-2的缀合物及其用途
WO2023004004A1 (en) * 2021-07-23 2023-01-26 Merck Sharp & Dohme Llc Il-2 muteins for treating cancer or infection
JP2024538042A (ja) * 2021-10-13 2024-10-18 シートムエックス セラピューティクス，インコーポレイテッド 三量体活性化可能サイトカイン構成体ならびに関連する組成物及び方法
CN118510795A (zh) * 2022-01-07 2024-08-16 苏州克睿基因生物科技有限公司 新型白介素-2多肽
AU2023211165A1 (en) * 2022-01-31 2024-07-25 Aarhus Universitet A biopharmaceutical prodrug platform based on protein conformational change
MX2024009715A (es) * 2022-02-11 2024-08-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Inmunoconjugado y su uso del mismo.
AU2023226005A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
US20250186550A1 (en) * 2022-03-03 2025-06-12 Hainan Simcere Pharmaceutical Co., Ltd. Pharmaceutical composition of il2 mutant-antibody fc block fusion protein and use thereof
CN114853909A (zh) * 2022-05-13 2022-08-05 南京吉盛澳玛生物医药有限公司 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途
WO2023222886A1 (en) * 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins
AU2023332193A1 (en) * 2022-09-02 2025-04-17 Novimmune Sa Reciprocally masked antibody-cytokine fusion proteins and methods of use thereof
CN117917438A (zh) * 2022-10-21 2024-04-23 北京诺诚健华医药科技有限公司 抗体融合蛋白及其制备和应用
WO2024119193A2 (en) * 2022-12-02 2024-06-06 AskGene Pharma, Inc. Mutant il-2 polypeptides and il-2 prodrugs
WO2024150174A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
US20240376170A1 (en) 2023-01-11 2024-11-14 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
GB202301945D0 (en) 2023-02-10 2023-03-29 Mount Natalie Novel immunoconjugates
EP4450093A1 (en) 2023-04-17 2024-10-23 Synaffix B.V. Cleavable immune cell engagers
WO2024218162A1 (en) 2023-04-17 2024-10-24 Synaffix B.V. Cleavable immune cell engagers
WO2024261212A1 (en) * 2023-06-22 2024-12-26 Aarhus Universitet Multi-specific proteinaceous prodrug constructs
WO2025024658A1 (en) * 2023-07-27 2025-01-30 Binacea Pharma, Inc. Mutant il-2 fusions with immune cell specific binding proteins and methods of use thereof
US20250197467A1 (en) 2023-08-23 2025-06-19 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
CN120813378A (zh) * 2023-12-04 2025-10-17 奥美药业有限公司 包含掩蔽的il-2的嵌合蛋白
US20250179137A1 (en) * 2023-12-05 2025-06-05 Regeneron Pharmaceuticals, Inc. Il18 receptor agonists and methods of use thereof
WO2025165594A1 (en) * 2024-02-02 2025-08-07 Staidson Biopharma Inc. Anti-pd-l1 and il-15 prodrug bifunctional protein and uses thereof
WO2025162454A1 (zh) * 2024-02-02 2025-08-07 北京昌平实验室 双特异性抗体和细胞因子融合蛋白及其应用
WO2025201242A1 (en) * 2024-03-25 2025-10-02 Tavotek Biotherapeutics (Hong Kong) Limited Antibodies targeting fap and lrrc15 and fusion proteins targeting hyaluronan and uses thereof
WO2026083295A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains
CN119639683A (zh) * 2024-12-21 2025-03-18 浙江大学绍兴研究院 一种表达il-15靶向b7h3的嵌合抗原受体-t细胞及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
DE10045592A1 (de) 2000-09-15 2002-03-28 Klaus Pfizenmaier Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie
WO2003015697A2 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
US8809504B2 (en) * 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
EP1723251A4 (en) * 2004-03-05 2008-04-23 Novartis Vaccines & Diagnostic IN VITRO TEST SYSTEM FOR THE FORECASTING THE COMPATIBILITY OF A PATIENT AGAINST THERAPEUTICS
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
PT2066796E (pt) 2006-09-20 2011-10-11 Mt Biomethan Gmbh Procedimento e dispositivo para a separação do metano e do dióxido de carbono do biogás
US20090304719A1 (en) * 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
US20110274650A1 (en) 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
JP5587975B2 (ja) * 2009-04-07 2014-09-10 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異的抗−ＥｒｂＢ−３／抗−ｃ−Ｍｅｔ抗体
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
KR102591732B1 (ko) 2010-11-12 2023-10-19 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
HUE029139T2 (hu) 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
ES2657856T3 (es) 2011-03-02 2018-03-07 Roche Glycart Ag Anticuerpos CEA
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
JP6499087B2 (ja) * 2013-02-26 2019-04-10 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
US9540440B2 (en) * 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
AU2014377106B2 (en) * 2014-01-08 2019-10-03 Jiangsu Hengrui Medicine Co., Ltd. IL-15 heterodimeric protein and uses thereof
WO2016023040A1 (en) * 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
SI3482766T1 (sl) * 2014-08-11 2020-09-30 Delinia, Inc. Spremenjene variante IL-2, ki selektivno aktivirajo regulatorne T celice za zdravljenje avtoimunskih bolezni
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
SG11201804038VA (en) * 2016-01-08 2018-06-28 Univ California Conditionally active heterodimeric polypeptides and methods of use thereof
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン

Similar Documents

Publication Publication Date Title
WO2019173832A4 (en) Cytokine prodrugs
JP2021530243A5 (enExample)
Forsberg et al. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen
CN112534052B (zh) 全新il-21前药及使用方法
CN114401997A (zh) 细胞因子前药和双前药
JP2022169543A (ja) 改善された養子ｔ細胞療法
JP6700325B2 (ja) 抗原をトランスフェクトされたｔ細胞を伴う二重特異性抗体分子及び医薬におけるそれらの使用
JP2022545439A5 (enExample)
Stork et al. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G
JP3860398B2 (ja) サイトカインの免疫複合体
JP2022536898A (ja) 新規ｉｌ－１５プロドラッグおよびその使用方法
JP2022542886A (ja) プロテアーゼ活性化治療剤を含む組成物および方法
CN114901679A (zh) 全新被掩蔽的细胞因子及其应用
JP2022512043A5 (enExample)
JP2022545439A (ja) 新規ｉｌ－２１プロドラッグおよびその使用方法
JP2021521822A5 (enExample)
JP2023123649A5 (enExample)
US20240218065A1 (en) Multispecific antigen-binding protein and use thereof
CN115232209A (zh) 靶向gprc5d的抗体及其用途
EP4121458A1 (en) Guidance and navigation control (gnc) antibody-like proteins and methods of making and using thereof
CN113646328A (zh) 一种免疫细胞因子及其制备与用途
CN117157312A (zh) 蛋白酶活化的多肽
JP2023523083A5 (enExample)
TWI869544B (zh) 雙特異性結合分子
CN114853880A (zh) Wt1抗原特异性t细胞受体及其抗肿瘤用途